

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

HepAD38

RRID:CVCL_M177

Type: Cell Line

Proper Citation

RRID:CVCL_M177

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_M177

Proper Citation: RRID:CVCL_M177

Description: Cell line HepAD38 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hepatoblastoma

Defining Citation: [PMID:9257747](#), [PMID:9875378](#), [PMID:21331898](#)

Comments: Virology: Inducibly expresses a hepatitis B virus (HBV) genome under the control of a tet operator/CMV promoter. Upon removal of tetracycline the cell line produces viral RNA and secrete virus-like particles into the supernatant., Biotechnology: Used in a bioassay that permits the large-scale screening of compound libraries for inhibitors of HBV replication., Population: Caucasian., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HepAD38

Synonyms: Hep AD38, HepG2 AD38, HepG2-AD38, Hep G2 AD 38, AD-38, AD38

Cross References: BTO:BTO_0006298, ATCC:CRL-3561, ATCC:CRL-12077, cancercellines:CVCL_M177, Wikidata:Q54882829

ID: CVCL_M177

Hierarchy: cvcl_0027

Record Creation Time: 20220427T220335+0000

Record Last Update: 20260905T180249+0000

Ratings and Alerts

No rating or validation information has been found for HepAD38.

Warning: Discontinued: ATCC; CRL-12077

Virology: Inducibly expresses a hepatitis B virus (HBV) genome under the control of a tet operator/CMV promoter. Upon removal of tetracycline the cell line produces viral RNA and secrete virus-like particles into the supernatant., Biotechnology: Used in a bioassay that permits the large-scale screening of compound libraries for inhibitors of HBV replication., Population: Caucasian., Group: Patented cell line.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 245 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Li C, et al. (2026) Scavenger receptor class F member 2 is an intracellular receptor for hepatitis B virus. *Cell*, 189(14), 4454.

Zhang R, et al. (2026) TRMT6-Mediated m1A Modification of CDK9 mRNA is a Dual-Pronged Pathogenic Driver for HBV-Related Hepatocellular Carcinoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(39), e14172.

Chen L, et al. (2025) A Galactose-Engineered Dual-Responsive Nanocarrier for ASO/CRISPR-Cas9 Delivery to Inhibit HBV Replication. *Advanced healthcare materials*, e02835.

Shi Y, et al. (2023) Release of hepatitis B virions is positively regulated by glucose-regulated protein 78 through direct interaction with preS1. *Journal of medical virology*, 95(1), e28271.

Hofmann S, et al. (2023) SUMO Modification of Hepatitis B Virus Core Mediates Nuclear Entry, Promyelocytic Leukemia Nuclear Body Association, and Efficient Formation of Covalently Closed Circular DNA. *Microbiology spectrum*, 11(3), e0044623.

Zheng Y, et al. (2023) Hepatitis B virus hijacks TSG101 to facilitate egress via multiple vesicle bodies. *PLoS pathogens*, 19(5), e1011382.

Li YY, et al. (2023) Hepatitis B Virus Utilizes a Retrograde Trafficking Route via the Trans-Golgi Network to Avoid Lysosomal Degradation. *Cellular and molecular gastroenterology and hepatology*, 15(3), 533.

Saeed U, et al. (2023) PIN1 and PIN4 inhibition via parvulin impeded Juglone, PiB, ATRA, 6,7,4'-THIF, KPT6566, and EGCG thwarted hepatitis B virus replication. *Frontiers in microbiology*, 14, 921653.

Yang Y, et al. (2023) O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. *Signal transduction and targeted therapy*, 8(1), 63.

Legrand AF, et al. (2023) Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity. *Hepatology communications*, 7(5).

Jabeen K, et al. (2023) Restoration of IL-11 and IL-15 cytokine production post calcium modulators and ROS treatment can assist viral clearance both in vitro and in vivo. *Iranian journal of basic medical sciences*, 26(2), 176.

Cai J, et al. (2023) Plerixafor and resatorvid inhibit hepatitis B virus in vitro by upregulating elongation factor Tu GTP-binding domain containing 2. *Frontiers in cellular and infection microbiology*, 13, 1118801.

Xie C, et al. (2023) Lnc-AIFM2-1 promotes HBV immune escape by acting as a ceRNA for miR-330-3p to regulate CD244 expression. *Frontiers in immunology*, 14, 1121795.

Zuo D, et al. (2023) A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo. *Protein & cell*, 14(1), 37.

Burm R, et al. (2023) Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections. *Gut*, 72(6), 1186.

Chen J, et al. (2023) A functional variant of CD40 modulates clearance of hepatitis B virus in hepatocytes via regulation of the ANXA2/CD40/BST2 axis. *Human molecular genetics*, 32(8), 1334.

Wang Y, et al. (2023) HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression. *Cancer research*, 83(7), 1048.

Yuan S, et al. (2023) HBV X Protein Induces Degradation of UBXN7, a Novel Negative Regulator of NF- κ B Signaling, to Promote HBV Replication. *Cellular and molecular gastroenterology and hepatology*, 15(1), 179.

Liu Y, et al. (2023) Apolipoprotein H induces sex-specific steatohepatitis and gut dysbiosis during chronic hepatitis B infection. *iScience*, 26(3), 106100.

Burdette D, et al. (2023) Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection. *Antimicrobial agents and chemotherapy*, 67(1), e0134822.